Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma

Trial Profile

A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs CS 1001 (Primary)
  • Indications T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors CStone Pharmaceuticals
  • Most Recent Events

    • 19 Jun 2018 New trial record
    • 13 Jun 2018 According to a CStone Pharmaceuticals media release, first patient has been enrolled in this trial and it is being conducted at the Sun Yat-sen University Cancer Center and the Beijing Cancer Hospital. Also, results from this and another trial (CS1001-202) will be used to support the registration application for CS-1001.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top